Medical Technology and Devices (MTD) is pleased to announce the successful closing of the acquisition of Ypsomed's Pen Needles and Blood Glucose Monitoring Systems (BGM) businesses, a strategic acquisition initially announced at the end of March. This acquisition marks a major step forward in MTD's mission to provide superior diabetes and obesity care solutions on a global scale.

Strengthening Our Position as the World's #2 Player by Increasing Production Capacity to Over 2.5 Billion Pen Needles

With this acquisition, MTD strengthens its position as the clear number two in the global pen needles market. This strategic acquisition not only solidifies our leadership in diabetes care but also underscores our commitment to delivering cutting-edge solutions for both self-care and professional use. We will integrate Ypsomed's pen needles operations into our European production and distribution network, bringing our total production capacity to over 2.5 billion pen needles.

An Exclusive Portfolio Designed to Comprehensively Cover More Patients, Consumers, and Healthcare Professionals

The integration of Ypsomed's businesses brings a wealth of advanced technologies and trademarks to MTD's diabetes and obesity portfolio, complementing our current product offering, which includes the G34, the thinnest and shortest pen needle on the market. With this acquisition, MTD strengthens its unique positioning by being able to supply a complete range of pen needles with 3, 5, and 6 bevels, Click Technology for an easy and secure fit, and single and dual protection in safety pen needles. Additionally, we have recently launched Continuous Glucose Monitoring Systems (CGMs), with tenders won in Italy marking our entry into this segment this year. This exclusive diabetes care portfolio underscores our ongoing commitment to innovation in both professional and consumer health. It includes medical sharps like the Safety Blood Collection Needle, the Vet Catheter, and the new Passive Safety Needle, Pic Protecto. Our 2024 consumer launches feature the new Blood Pressure Monitoring Systems (BPMs), nebulizers, footcare products, and insect repellents.

Reaching 3 Billion New Consumers by Entering the Chinese and Indian Markets

The acquisition provides entry into strategic, high-growth markets such as China and India, while also enhancing our presence in established markets, including North America, Germany, and France. This expansion is a pivotal step for MTD as we continue to expand our global reach and influence within the diabetes care industry.

Investing in a Cutting-Edge, State-of-the-Art Production Facility

In line with its growth and continuous improvement strategy, MTD is implementing a substantial investment plan to establish the most competitive production facilities for pen needles and lancets in Europe. These investments aim to increase capacity and further enhance the performance, quality, and ESG credentials of our production operations.

CEO Statement

"The completion of this acquisition marks a transformative moment for MTD Group. By integrating Ypsomed's Pen Needles and Blood Glucose Monitoring businesses, we solidify our position as a global leader in diabetes care and establish ourselves as the second-largest producer of pen needles worldwide. This strategic move enhances our ability to deliver innovative, high-quality solutions to our customers and expands our reach into key markets. Our significant investments underscore our commitment to scaling our operations efficiently while maintaining the highest standards of quality. We are excited about the opportunities this acquisition presents and remain dedicated to advancing the future of diabetes care," said Charles Bouaziz, CEO of MTD Group.

MTD was supported by Studio Legale LCA for the legal aspects, with Roberto de Bonis, Sara Consoli, and Mario Niggeler operations.